Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.

Acta pharmacologica Sinica - 1 Jun 2024

Han Rui, Lu Cong-Hua, Hu Chen, Dou Yuan-Yao, Kang Jun, Lin Cai-Yu, Wu Di, Jiang Wei-Ling, Yin Guo-Qing, He Yong

Abstract excerpt

In addition to the classical resistance mechanisms, receptor tyrosine-protein kinase AXL is a main mechanism of resistance to third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) osimertinib in EGFR-mutated non-small cell lung cancer (NSCLC). Developing an effective AXL inhibitor is important to sensitize osimertinib in clinical application. In this study we assessed the efficacy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Axl Receptor Tyrosine Kinase

Share to Indoles

Share to Organophosphorus Compounds

Share to Pyrimidines

Share to Receptor Protein-Tyrosine Kinases

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 38438582
DOI: 10.1038/s41401-024-01237-4
PMCID: PMC11130302

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.PMID 38438582Read ↗

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer CellsSemantic proximity Read ↗

Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis.Semantic proximity Read ↗

High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.Semantic proximity Read ↗

Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.Semantic proximity Read ↗

The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

AXL up-regulates PD-L1 inducing gefitinib resistance in EGFR mutated NSCLCSemantic proximity Read ↗

Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer CellsSemantic proximity Read ↗

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer.Semantic proximity Read ↗

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.Semantic proximity Read ↗

Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.